Trial from ClinicalTrials.gov

For full trial details, please see the original record at



Trial ID
NCT02247804
Ethics application status
Date submitted
22/09/2014
Date registered
22/09/2014
Date last updated
15/06/2017

Titles & IDs
Public title
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension
Scientific title
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Secondary ID [1] 0 0
2014-003037-26
Secondary ID [2] 0 0
192024-091
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Glaucoma, Open-Angle 0 0
Ocular Hypertension 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Hypertension
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: drugs - Bimatoprost sustained-release
Other interventions - Sham
Treatment: drugs - Timolol
Treatment: drugs - Timolol Vehicle (placebo)

Experimental: Bimatoprost SR Dose A - Study Eye: bimatoprost sustained-release (SR) Dose A administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.

Experimental: Bimatoprost SR Dose B - Study Eye: bimatoprost SR Dose B administered on Day 1, Week 16, and Week 32; timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.

Sham Comparator: Sham - Both Eyes: sham administered on Day 1, Week 16, and Week 32; timolol administered once in the morning and once in the evening for up to 20 months.


Treatment: drugs: Bimatoprost sustained-release
Bimatoprost sustained-release (SR) administered in the study eye on Day 1, Week 16, and Week 32.

Other interventions: Sham
Sham administered on Day 1, Week 16, and Week 32, as per protocol.

Treatment: drugs: Timolol
Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.

Treatment: drugs: Timolol Vehicle (placebo)
Timolol vehicle administered once in the morning and once in the evening for up to 20 months, as per protocol.

Intervention code [1] 0 0
Treatment: drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline in Intraocular Pressure (IOP) in the Study Eye
Timepoint [1] 0 0
Baseline, Week 12
Primary outcome [2] 0 0
IOP in the Study Eye
Timepoint [2] 0 0
Week 2
Primary outcome [3] 0 0
IOP in the Study Eye
Timepoint [3] 0 0
Week 6
Primary outcome [4] 0 0
IOP in the Study Eye
Timepoint [4] 0 0
Week 12
Secondary outcome [1] 0 0
Change from Baseline in IOP in the Study Eye
Timepoint [1] 0 0
Baseline, Week 2, Week 6

Eligibility
Key inclusion criteria
-Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes
require IOP-lowering treatment.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Previous enrollment in another Allergan Bimatoprost SR Study.

- Eye surgery (including cataract surgery) and/or any eye laser surgery within the past
6 months in the study eye

- Anticipated need for laser eye surgery in either eye within the first 52 weeks of the
study duration

- History of glaucoma surgery

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Current
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Vision Eye Institute Chatswood - Chatsworth
Recruitment hospital [2] 0 0
Melbourne Eye Specialists - Fitzroy
Recruitment hospital [3] 0 0
Waverley Eye Clinic - Glen Waverley
Recruitment hospital [4] 0 0
Marsden Eye Specialists, Parramatta - Paramatta
Recruitment hospital [5] 0 0
Preston Eye Clinic - Preston
Recruitment hospital [6] 0 0
Westmead Hospital - Westmead
Recruitment hospital [7] 0 0
Gosford & Wyong Eye Surgery - Wyong
Recruitment postcode(s) [1] 0 0
New South Wales - Chatsworth
Recruitment postcode(s) [2] 0 0
Victoria 3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
Vctoria 3150 - Glen Waverley
Recruitment postcode(s) [4] 0 0
New South Wales - Paramatta
Recruitment postcode(s) [5] 0 0
Victoria 3072 - Preston
Recruitment postcode(s) [6] 0 0
New South Wales - Westmead
Recruitment postcode(s) [7] 0 0
New South Wales - Wyong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
New Hampshire
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Utah
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
West Virginia
Country [29] 0 0
Austria
State/province [29] 0 0
Graz
Country [30] 0 0
Austria
State/province [30] 0 0
Salzburg
Country [31] 0 0
Austria
State/province [31] 0 0
Vienna
Country [32] 0 0
Austria
State/province [32] 0 0
Wien
Country [33] 0 0
Belgium
State/province [33] 0 0
Brugges
Country [34] 0 0
Belgium
State/province [34] 0 0
Brussels
Country [35] 0 0
Belgium
State/province [35] 0 0
Leuven
Country [36] 0 0
Belgium
State/province [36] 0 0
Liege
Country [37] 0 0
Brazil
State/province [37] 0 0
Goias
Country [38] 0 0
Brazil
State/province [38] 0 0
Minas Gerais
Country [39] 0 0
Brazil
State/province [39] 0 0
Parana
Country [40] 0 0
Brazil
State/province [40] 0 0
Sao Paulo
Country [41] 0 0
Brazil
State/province [41] 0 0
CEP
Country [42] 0 0
Brazil
State/province [42] 0 0
Goiania
Country [43] 0 0
Brazil
State/province [43] 0 0
Rio Verde
Country [44] 0 0
Chile
State/province [44] 0 0
Rancagua
Country [45] 0 0
Chile
State/province [45] 0 0
Santiago
Country [46] 0 0
China
State/province [46] 0 0
Taiwan
Country [47] 0 0
Denmark
State/province [47] 0 0
Glostrup Copenhagen
Country [48] 0 0
Denmark
State/province [48] 0 0
Roskilde
Country [49] 0 0
France
State/province [49] 0 0
Gironde
Country [50] 0 0
France
State/province [50] 0 0
Besancon Cedex
Country [51] 0 0
France
State/province [51] 0 0
Clermont-Ferrand Cedex 01
Country [52] 0 0
France
State/province [52] 0 0
Dijon
Country [53] 0 0
France
State/province [53] 0 0
Grenoble
Country [54] 0 0
France
State/province [54] 0 0
Limoges Cedex
Country [55] 0 0
France
State/province [55] 0 0
Lyon
Country [56] 0 0
France
State/province [56] 0 0
Nice Cedex
Country [57] 0 0
France
State/province [57] 0 0
Paris
Country [58] 0 0
France
State/province [58] 0 0
St. Herblain
Country [59] 0 0
France
State/province [59] 0 0
Tarves
Country [60] 0 0
France
State/province [60] 0 0
Tours Cedex F
Country [61] 0 0
Hong Kong
State/province [61] 0 0
Hong Kong
Country [62] 0 0
Hungary
State/province [62] 0 0
Budapest
Country [63] 0 0
Hungary
State/province [63] 0 0
Debrecen
Country [64] 0 0
Hungary
State/province [64] 0 0
Pecs
Country [65] 0 0
Hungary
State/province [65] 0 0
Szeged
Country [66] 0 0
Hungary
State/province [66] 0 0
Szombathely
Country [67] 0 0
Hungary
State/province [67] 0 0
Zalaegerszeg
Country [68] 0 0
Israel
State/province [68] 0 0
Afula
Country [69] 0 0
Israel
State/province [69] 0 0
Ashkelon
Country [70] 0 0
Israel
State/province [70] 0 0
Beer Sheva
Country [71] 0 0
Israel
State/province [71] 0 0
Beer-Yaakov
Country [72] 0 0
Israel
State/province [72] 0 0
Haifa
Country [73] 0 0
Israel
State/province [73] 0 0
Holon
Country [74] 0 0
Israel
State/province [74] 0 0
Kfar-Saba
Country [75] 0 0
Israel
State/province [75] 0 0
Petach Tiqva
Country [76] 0 0
Israel
State/province [76] 0 0
Rehovot
Country [77] 0 0
Israel
State/province [77] 0 0
Tel Aviv
Country [78] 0 0
Peru
State/province [78] 0 0
Lima
Country [79] 0 0
Philippines
State/province [79] 0 0
National Capital Region
Country [80] 0 0
Philippines
State/province [80] 0 0
Makati
Country [81] 0 0
Poland
State/province [81] 0 0
Bydgoszcz
Country [82] 0 0
Poland
State/province [82] 0 0
Gdansk
Country [83] 0 0
Poland
State/province [83] 0 0
Katowice
Country [84] 0 0
Poland
State/province [84] 0 0
Lodz
Country [85] 0 0
Poland
State/province [85] 0 0
Lublin
Country [86] 0 0
Poland
State/province [86] 0 0
Naleczow
Country [87] 0 0
Poland
State/province [87] 0 0
Nowy Targ
Country [88] 0 0
Poland
State/province [88] 0 0
Olsztyn
Country [89] 0 0
Poland
State/province [89] 0 0
Warsaw
Country [90] 0 0
Poland
State/province [90] 0 0
Warszawa
Country [91] 0 0
Poland
State/province [91] 0 0
Wroclaw
Country [92] 0 0
Spain
State/province [92] 0 0
Cadiz
Country [93] 0 0
Spain
State/province [93] 0 0
A Coruna
Country [94] 0 0
Spain
State/province [94] 0 0
Alicante
Country [95] 0 0
Spain
State/province [95] 0 0
Barcelona
Country [96] 0 0
Spain
State/province [96] 0 0
Bilbao
Country [97] 0 0
Spain
State/province [97] 0 0
Cordoba
Country [98] 0 0
Spain
State/province [98] 0 0
Huelva
Country [99] 0 0
Spain
State/province [99] 0 0
Madrid
Country [100] 0 0
Spain
State/province [100] 0 0
Pamplona
Country [101] 0 0
Spain
State/province [101] 0 0
Salamanca
Country [102] 0 0
Spain
State/province [102] 0 0
Sevilla
Country [103] 0 0
Spain
State/province [103] 0 0
Valencia
Country [104] 0 0
Spain
State/province [104] 0 0
Valladolid
Country [105] 0 0
Spain
State/province [105] 0 0
Zaragoza
Country [106] 0 0
Switzerland
State/province [106] 0 0
Geneva
Country [107] 0 0
Switzerland
State/province [107] 0 0
Geneve
Country [108] 0 0
Switzerland
State/province [108] 0 0
Lausanne
Country [109] 0 0
Switzerland
State/province [109] 0 0
Zurich
Country [110] 0 0
Taiwan
State/province [110] 0 0
Hualien
Country [111] 0 0
Taiwan
State/province [111] 0 0
Republic of China
Country [112] 0 0
Taiwan
State/province [112] 0 0
Kaohsiung

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Allergan
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in
patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month
treatment period with an 8-month extended follow-up.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Margot Goodkin
Address 0 0
Allergan
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Trial Registry Team
Address 0 0
Country 0 0
Phone 0 0
877-277-8566
Fax 0 0
Email 0 0
IR-CTRegistration@Allergan.com
Contact person for scientific queries
Contact person responsible for updating information